UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)

被引：0
|
作者：
Talpaz, M. [1 ]
Jamieson, C. [2 ]
Gabrail, N. [3 ]
Lebedinsky, C. [4 ]
Gao, G. [4 ]
Patki, A. [4 ]
Lui, F. [4 ]
Tefferi, A. [5 ]
Pardanani, A. [5 ]
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[2] Moores UCSD Canc Ctr, Dept Med, La Jolla, CA USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Sanofi Oncol, Cambridge, MA USA
[5] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1113
引用
收藏
页码：458 / 458
页数：1
相关论文
共 50 条
  • [41] MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
    Mascarenhas, John
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro M.
    Berry, Tymara
    Redding, Denise
    Sherman, Laurie
    Dougherty, Souria
    Peng, Lixian
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Verstovsek, Srdan
    BLOOD, 2022, 140 : 6826 - 6829
  • [42] Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
    Kiladjian, Jean-Jacques
    Heidel, Florian H.
    Vannucchi, Alessandro M.
    Ribrag, Vincent
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Martino, Bruno
    Kindler, Thomas
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Gopalakrishna, Prashanth
    Ide, Susan E.
    Loechner, Sabine
    Mu, Song
    Harrison, Claire N.
    BLOOD, 2014, 124 (21)
  • [43] A Phase 2b dose-ranging trial of baricitinib, an oral JAM 1/JAK 2 inhibitor, in patients with moderate-to-severe psoriasis: Results from the randomized withdrawal and re-treatment periods
    Papp, Kim
    Menter, Alan
    Raman, Mani
    Janes, Jonathan
    Disch, Damon
    Macias, William
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S7 - S7
  • [44] Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
    Connolly, Stuart J.
    Eikelboom, John
    Dorian, Paul
    Hohnloser, Stefan H.
    Gretler, Daniel D.
    Sinha, Uma
    Ezekowitz, Michael D.
    EUROPEAN HEART JOURNAL, 2013, 34 (20) : 1498 - 1505
  • [45] Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay.
    Liu, Feng
    Talpaz, Moshe
    Pardanani, Animesh
    Jamieson, Catriona
    Gabrail, Nashat
    Tefferi, Ayalew
    Lei, Tianlei
    Greco, Rita
    Adrian, Francisco
    Daskalakis, Nikki
    Lebedinsky, Claudia
    Cohen, Pamela
    Bergstrom, Donald
    CANCER RESEARCH, 2013, 73 (08)
  • [46] The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis
    Tremblay, Douglas
    Cavalli, Lara
    Sy, Oumar
    Rose, Shelonitda
    Mascarenhas, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E463 - E466
  • [47] 12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
    Tanaka, Yoshiya
    Emoto, Kahaku
    Tsujimoto, Mika
    Schlichting, Douglas E.
    Macias, William
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S765
  • [48] Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
    Harrison, Claire N.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Jourdan, Eric
    Silver, Richard T.
    Schouten, Harry C.
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Rose, Shelonitda
    Tang, Derek
    Hu, Angela
    Guo, Shien
    Liao, Weiqin
    Brownstein, Carrie
    Mesa, Ruben A.
    BLOOD, 2019, 134
  • [49] Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
    Landgren, Ola
    Cavo, Michele
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter M.
    Estell, Jane
    Sandhu, Irwindeep
    Jenner, Matthew
    Williams, Catherine
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Goldschmidt, Hartmut
    Moreau, Philippe
    Kuppens, Steven
    Bandekar, Rajesh
    Neff, Tobias
    Cortoos, Annelore
    Clemens, Pamela L.
    Qi, Ming
    Adams, Homer, III
    Hofmeister, Craig C.
    BLOOD, 2018, 132
  • [50] 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Taylor, Peter
    Genovese, Mark
    Keystone, Edward C.
    Drescher, Edit
    Berclaz, Pierre-Yves
    Lee, Chin
    Fidelus-Gort, Rosalind
    Schlichting, Douglas
    Beattie, Scott
    Luchi, Monica
    Macias, William
    RHEUMATOLOGY, 2013, 52 : 44 - 45
12345